logo
Plus   Neg
Share
Email

Astellas, Adaptimmune To Co-Develop And Co-Commercialize T-cell Therapies

Tokyo, Japan-based Astellas Pharma Inc. (ALPMY) announced Tuesday an agreement with Adaptimmune Therapeutics plc (ADAP), which is focused on cell therapy to treat cancer, to develop up to three T-cell therapies.

Under the deal, Astellas unit Universal Cells, Inc, and Adaptimmune will co-develop and co-commercialize new stem-cell derived allogeneic T-cell therapies to people with cancer.

Under the terms, Adaptimmune will receive an upfront payment of $50 million, and may receive up to $897.5 million in payments.

Along with upfront payment, the potential payments for Adaptimmune includes development milestones totaling up to $73.75 million for each product if the collaboration product discovered in this partnership is co-developed and commercialized by both companies. It also includes up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Astellas.

In addition, Adaptimmune will receive research funding of up to $7.5 million per year. Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Under the terms of the agreement, Astellas may receive up to $552.5 million, including up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune. In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune.

Astellas will fund research up until completion of a Phase 1 trial for each candidate.

The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.

On Nasdaq, Adaptimmune shares gained 200 percent on Monday's regular trading to $3.99. In the after hours trading, stock fell 5 percent to $3.80.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
RELATED NEWS
Follow RTT